|
01/24/2012 02:00 AM
|
|
Brain MRIs May Provide An Early Diagnostic Marker For Dyslexia
|
Children at risk for dyslexia show differences in brain activity on MRI scans even before they begin learning to read, finds a study at Children's Hospital Boston. Since developmental dyslexia responds to early intervention, diagnosing children at risk before or during kindergarten could head off difficulties and frustration in school, the researchers say...
|
|
01/20/2012 08:00 AM
|
|
Human Hookworm Vaccine Trial
|
The Na-GST-1 antigen, a candidate for the first human hookworm vaccine developed by the Sabin Vaccine Institute (Sabin), has entered a Phase 1 human trial in Brazil, according to Sabin. For the vaccine product development partnership (PDP) headquartered at Sabin, the clinical trial is a considerable achievement. Worldwide, almost 600 million individuals are infected by human hookworm...
|
|
01/20/2012 08:00 AM
|
|
Impetigo - Ozenoxacin Phase lll Trial
|
The pharmaceutical company Ferrer has received approval to start phase III human trials of ozenoxacin, formulated as a topical treatment for infectious skin conditions. In February 2012, participants are expected to enter the multicenter, randomized, placebo controlled, parallel, double-blinded superiority clinical study, which is scheduled to complete in 2013...
|
|
01/18/2012 03:00 AM
|
|
New Drug For Advanced Colorectal Cancer Shows Promise In Trial
|
An experimental drug for advanced colorectal cancer that available treatments have failed to halt, has shown promise in a clinical trial, says Bayer HealthCare, the company that makes it. The results of the phase III trial show that compared to placebo, regorafenib slowed tumor growth and extended survival...
|
|
01/17/2012 12:00 PM
|
|
Medivation And Pfizer Axe their new Alzheimer's drug Dimebon
|
Pfizer Inc. and Medivation, Inc. announced results from their 'CONCERT' trial today. CONCERT is a Phase 3 trial that evaluated dimebon (latrepirdine), which is used to treat patients with mild-to-moderate Alzheimer's disease. Dimebon is added to ongoing treatment with donepezil HCL tablets...
|
|
01/17/2012 02:00 AM
|
|
Preoperative Breast Cancer Treatment May Be Improved By Combining 2 Anti-HER2 Drugs
|
Using two drugs that inhibit the growth factor HER2 for preoperative treatment of early-stage HER2-positive breast cancer appears to have better results than treatment with a single agent...
|
|
01/16/2012 10:00 AM
|
|
Research Misconduct Revealed in UK
|
A BMJ survey revealed that over one in ten (13%) UK based scientists or doctors have witnessed that colleagues intentionally changed or fabricated data during their research in order to get published, whilst 6% of respondents reported they are aware of possible research misconduct at their institution, that has not been accurately investigated...
|
|
|
• Home
• FDA News
• Medicines
• Cancer
• Heart Disease
• Articles
|
|
02/06/2012 07:00 AM
|
|
Healthy People Co. Dietary Supplements: Recall - Undeclared Drug Ingredient
|
Recalled products pose significant risk to patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke.
|
|
02/03/2012 02:18 PM
|
|
Gris-PEG (griseofulvin ultramicrosize): Health Advisory - Risk of Product Mix-Up
|
During packaging and labeling, tablets from one product type may have carried over into packaging of another product.
|
|
02/03/2012 07:06 AM
|
|
Acetylcysteine Solution, USP (Roxane Laboratories, Inc.): Recall - Visible Glass Particle
|
Use of an inhaled product with glass particles has the potential to cause choking which could be life-threatening.
|
|
02/01/2012 05:25 AM
|
|
Lo/Ovral-28 (Norgestrel/EthinylEstradiol) Tablets: Recall - Possibility of Inexact Tablet Counts or Out of Sequence Tablets
|
Oral contraceptive daily regimen may be incorrect and could leave women without adequate contraception, and at risk for unintended pregnancy.
|
|
01/31/2012 10:10 AM
|
|
Vitaflo USA Renastart: Recall - Possible Health Risk Due To Incorrectly Labeled Cans
|
Consequences of using the incorrectly labeled product may result in high potassium blood levels (hyperkalemia) or high sodium levels in the blood (hypernatremia).
|
|
01/30/2012 05:50 AM
|
|
Treanda (bendamustine HCL): Recall - Particulate Matter in Vial
|
Potential adverse events after intravenous administration of solutions containing particulates may include emboli and result in disruption of blood flow, causing tissue/organ damage.
|
|
01/20/2012 02:30 PM
|
|
Tysabri (natalizumab): Drug Safety Communication - New Risk Factor for Progressive Multifocal Leukoencephalopathy (PML)
|
The risks and benefits of continuing treatment with Tysabri should be carefully considered in patients who are found to be anti-JCV antibody positive and have one or more of the other known risk factors for PML.
|
|
01/20/2012 11:55 AM
|
|
Perfect Image Solutions Topical Hair Regrowth Products: Recall - Unapproved Drugs, Risk of Health Hazards
|
Systemic absorption of topically administered Minoxidil could cause low blood pressure, heart palpitations and associated cardiac symptoms.
|
|
01/20/2012 10:20 AM
|
|
Vagifresh Ball, Vagifresh Gel, Female One: Recall - Undeclared Drug Ingredient, Bacterial Contamination
|
Possibility of an adverse reaction or unknown drug-drug interaction.
|
|
01/13/2012 09:01 AM
|
|
Adcetris (brentuximab vedotin): Drug Safety Communication - Progressive Multifocal Leukoencephalopathy and Pulmonary Toxicity
|
New Boxed Warning and Contraindication highlighting these risks added to product labeling.
|
|
|